• Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., 2020.The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830–833.

  • Bos, R., Rutten, L., van der Lubbe, J.E., Bakkers, M.J., Hardenberg, G., Wegmann, F., Zuijdgeest, D., de Wilde, A.H., Koornneef, A., Verwilligen, A., 2020. Ad26 vectorbased COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines 5, 91.

  • Capone, S., Raggioli, A., Gentile, M., Battella, S., Lahm, A., Sommella, A., Contino, A.M., Urbanowicz, R.A., Scala, R., Barra, F., 2021. Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19. Mol. Ther. 29, 2412–2423.

  • Elkashif, A., Alhashimi, M., Sayedahmed, E.E., Sambhara, S., Mittal, S.K., 2021.Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections. Clin. Transl. Immunology 10, e1345.

  • Ge, J., Wang, R., Ju, B., Zhang, Q., Sun, J., Chen, P., Zhang, S., Tian, Y., Shan, S., Cheng, L., 2021. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Nat. Commun. 12, 250.

  • Hassan, A.O., Case, J.B., Winkler, E.S., Thackray, L.B., Kafai, N.M., Bailey, A.L., McCune, B.T., Fox, J.M., Chen, R.E., Alsoussi, W.B., 2020. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 182, 744–753.

  • Heath, P.T., Galiza, E.P., Baxter, D.N., Boffito, M., Browne, D., Burns, F., Chadwick, D.R., Clark, R., Cosgrove, C., Galloway, J., 2021. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine. N. Engl. J. Med. 385, 1172–1183.

  • Huang, Q., Ji, K., Tian, S., Wang, F., Huang, B., Tong, Z., Tan, S., Hao, J., Wang, Q., Tan, W., 2021. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nat. Commun. 12, 776.

  • JHU, 2021. COVID-19 Dashboard by the Center for Systems Science and Engineering(CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html.

  • Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J.S., Zhu, M., Cloney-Clark, S., Zhou, H., 2020. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 383, 2320–2332.

  • Kerstetter, L.J., Buckley, S., Bliss, C.M., Coughlan, L., 2021. Adenoviral vectors as vaccines for emerging avian influenza viruses. Front. Immunol. 11, 607333.

  • Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao, K., Kent, S.J., Triccas, J.A., Davenport, M.P., 2021. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211.

  • Laczkó, D., Hogan, M.J., Toulmin, S.A., Hicks, P., Lederer, K., Gaudette, B.T., Castaño, D., Amanat, F., Muramatsu, H., Oguin III, T.H., Ojha, A., Zhang, L., Mu, Z., Parks, R., Manzoni, T.B., Roper, B., Strohmeier, S., Tombácz, I., Arwood, L., Nachbagauer, R., Karikó, K., Greenhouse, J., Pessaint, P., Porto, M., Putman-Taylor, T., Strasbaugh, A., Campbell, T., Lin, P.J.C., Tam, Y.K., Sempowski, G.D., Farzan, M., Choe, H., Saunders, K.O., Haynes, B.F., Andersen., H., Eisenlohr, L.C., Weissman, D., Krammer, F., Bates, P., Allman, D., Locci, M., Pardi, N., 2020. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity 53, 724–732.

  • Li, W., Chen, C., Drelich, A., Martinez, D.R., Gralinski, L.E., Sun, Z., Schäfer, A., Kulkarni, S.S., Liu, X., Leist, S.R., 2020. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. Proc. Natl. Acad. Sci. U.S.A. 117, 29832–29838.

  • Li, K., Meyerholz, D.K., Bartlett, J.A., McCray Jr., P.B., 2021a. The TMPRSS2 inhibitor nafamostat reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19. mBio 12, e0097021.

  • Li, M., Guo, J., Lu, S., Zhou, R., Shi, H., Shi, X., Cheng, L., Liang, Q., Liu, H., Wang, P., Wang, N., Wang, Y., Fu, L., Xing, M., Wang, R., Ju, B., Liu, L., Lau, S.-Y., Jia, W., Tong, X., Yuan, L., Guo, Y., Qi, H., Zhang, Q., Huang, Z., Chen, H., Zhang, Z., Chen, Z., Peng, X., Zhou, D., Zhang, L., 2021b. Single-dose immunization with a chimpanzee adenovirus-based vaccine induces sustained and protective immunity against SARSCoV-2 infection. Front. Immunol. 12, 697074.

  • Liu, Q., Xiong, Q., Mei, F., Ma, C., Zhang, Z., Hu, B., Xu, J., Jiang, Y., Zhan, F., Zhou, S., Tao, L., Chen, X., Guo, M., Wang, X., Fang, Y., Shen, S., Liu, Y., Liu, F., Zhou, L., Xu, K., Ke, C., Deng, F., Cai, K., Yan, H., Chen, Y., Lan, K., 2021. Antibody neutralization to SARS-CoV-2 and variants after one year in Wuhan, China. Innovation 3, 100181.

  • Logunov, D.Y., Dolzhikova, I.V., Shcheblyakov, D.V., Tukhvatulin, A.I., Zubkova, O.V., Dzharullaeva, A.S., Kovyrshina, A.V., Lubenets, N.L., Grousova, D.M., Erokhova, A.S., 2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671–681.

  • Ma, X., Zou, F., Yu, F., Li, R., Yuan, Y., Zhang, Y., Zhang, X., Deng, J., Chen, T., Song, Z., 2020. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 53, 1315–1330.e9.

  • McMahan, K., Yu, J., Mercado, N.B., Loos, C., Tostanoski, L.H., Chandrashekar, A., Liu, J., Peter, L., Atyeo, C., Zhu, A., Bondzie, E.A., Dagotto, G., Gebre, M.S., Jacob-Dolan, C., Li, Z., Nampanya, F., Patel, S., Pessaint, L., Ry, A.V., Blade, K., Yalley-Ogunro, J., Cabus, M., Brown, R., Cook, A., Teow, E., Andersen, H., Lewis, M.J., Lauffenburger, D.A., Alter, G., Barouch, D.H., 2021. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630–634.

  • Mendonça, S.A., Lorincz, R., Boucher, P., Curiel, D.T., 2021. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines 6, 97.

  • Ong, S.W.X., Tan, Y.K., Chia, P.Y., Lee, T.H., Ng, O.T., Wong, M.S.Y., Marimuthu, K., 2020. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA 323, 1610–1612.

  • Palacios, R., Patiño, E.G., de Oliveira Piorelli, R., Conde, M.T.R.P., Batista, A.P., Zeng, G., Xin, Q., Kallas, E.G., Flores, J., Ockenhouse, C.F., 2020. Double-blind, randomized, placebo-controlled phase iii clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac-PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials 21, 853.

  • Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Marc, G.P., Moreira, E.D., Zerbini, C., Bailey, R., Swanson, K.A., Roychoudhury, S., Koury, K., Li, P., Kalina, W.V., Cooper D., Jr, R.W.F., Hammitt, L.L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D.B., Mather, S., Dormitzer, P.R., Şahin, U., Jansen, K.U., Gruber, W.C., C4591001 Clinical Trial Group, 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615.

  • Rathnasinghe, R., Strohmeier, S., Amanat, F., Gillespie, V.L., Krammer, F., GarcíaSastre, A., Coughlan, L., Schotsaert, M., Uccellini, M.B., 2020. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg. Microbes. Infect. 9, 2433–2445.

  • Scheuch, G., 2020. Breathing is enough: for the spread of influenza virus and SARS-CoV-2 by breathing only. J. Aerosol. Med. Pulm. Drug. Deliv. 33, 230–234.

  • Sun, J., Zhuang, Z., Zheng, J., Li, K., Wong, R.L.-Y., Liu, D., Huang, J., He, J., Zhu, A., Zhao, J., Li, X., Xi, Y., Chen, R., Alshukairi, A.N., Chen, Z., Zhang, Z., Chen, C., Huang, X., Li, F., Lai, X., Chen, D., Wen, L., Zhuo, J., Zhang, Y., Wang, Y., Huang, S., Dai, J., Shi, Y., Zheng, K., Leidinger, M.R., Chen, J., Li, Y., Zhong, N., Meyerholz, D.K., Jr, P.B.M., Perlman, S., Zhao, J., 2020a. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 182, 734–743e5.

  • Sun, S.-H., Chen, Q., Gu, H.-J., Yang, G., Wang, Y.-X., Huang, X.-Y., Liu, S.-S., Zhang, N.-N., Li, X.-F., Xiong, R., 2020b. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28, 124–133.e4.

  • Tostanoski, L.H., Wegmann, F., Martinot, A.J., Loos, C., McMahan, K., Mercado, N.B., Yu, J., Chan, C.N., Bondoc, S., Starke, C.E., Nekorchuk, M., Busman-Sahay, K., PiedraMora, C., Wrijil, L.M., Ducat, S., Custers, J., Atyeo, C., Fischinger, S., Burke, J.S., Feldman, J., Hauser, B.M., Caradonna, T.M., Bondzie, E.A., Dagotto, G., Gebre, M.S., Jacob-Dolan, C., Lin, Z., Mahrokhian, S.H., Nampanya, F., Nityanandam, R., Pessaint, L., Porto, M., Ali, V., Benetiene, D., Tevi, K., Andersen, H., Lewis, M.G., Schmidt, A.G., Lauffenburger, D.A., Alter, G., Estes, J.D., Schuitemaker, H., Zahn, R., Barouch, D.H., 2020. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat. Med. 26, 1694–1700.

  • van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J.N., Port, J.R., Avanzato, V.A., Bushmaker, T., Flaxman, A., Ulaszewska, M., Feldmann, F., Allen, E.R., Sharpe, H., Schulz, J., Holbrook, M., Okumura, A., Meade-White, K., Pérez-Pérez, L., Edwards, N.J., Wright, D., Bissett, C., Gilbride, C., Williamson, B.N., Rosenke, R., Long, D., Ishwarbhai, A., Kailath, R., Rose, L., Morris, S., Powers, C., Lovaglio, J., Hanley, P.W., Scott, D., Saturday, G., Wit, E.d., Gilbert, S.C., Munster, V.J., 2020. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586, 578–582.

  • Wang, H., Zhang, Y., Huang, B., Deng, W., Quan, Y., Wang, W., Xu, W., Zhao, Y., Li, N., Zhang, J., Liang, H., Bao, L., Xu, Y., Ding, L., Zhou, W., Gao, H., Liu, J., Niu, P., Zhao, L., Zhen, W., Fu, H., Yu, S., Zhang, Z., Xu, G., Li, C., Lou, Z., Xu, M., Qin, C., Wu, G., Gao, G.F., Tan, W., Yang, X., 2020. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182, 713–721.e9.

  • WHO, 2021a. Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued.

  • WHO, 2021b. COVID-19 vaccine tracker and landscape. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

  • Xu, K., An, Y., Li, Q., Huang, W., Han, Y., Zheng, T., Fang, F., Liu, H., Liu, C., Gao, P., Xu, S., Liu, X., Zhang, R., Zhao, X., Liu, W.J., Bi, Y., Wang, Y., Zhou, D., Wang, Q., Hou, W., Xia, Q., Gao, G.F., Dai, L., 2021. Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. Emerg. Microbes. Infect. 10, 1574–1588.

  • Yang, J., Wang, W., Chen, Z., Lu, S., Yang, F., Bi, Z., Bao, L., Mo, F., Li, X., Huang, Y., Hong, W., Yang, Y., Zhao, Y., Ye, F., Lin, S., Deng, W., Chen, H., Lei, H., Zhang, Z., Luo, M., Gao, H., Zheng, Y., Gong, Y., Jiang, X., Xu, Y., Lv, Q., Li, D., Wang, M., Li, F., Wang, S., Wang, G., Yu, P., Qu, Y., Yang, L., Deng, H., Tong, A., Li, J., Wang, Z., Yang, J., Shen, G., Zhao, Li, Y., Luo, J., Liu, H., Yu, W., Yang, M., Xu, J., Wang, J., Li, H., Wang, H., Kuang, D., Lin, P., Hu, Z., Guo, W., Cheng, W., He, Y., Song, X., Chen, C., Xue, Z., Yao, S., Chen, Lu., Ma, X., Chen, S., Gou, M., Huang, W., Wang, Y., Fan, C., Tian, Z., Shi, M., Wang, F.-S., Dai, L., Wu, M., Li, G., Wang, G., Peng, Y., Qian, Z., Huang, C., Lau, J.Y-N., Yang, Z., Wei, Y., Cen, X., Peng, X., Qin, C., Zhang, K., Lu, G., Wei, X., 2020. A vaccine targeting the RBD of the S protein of SARSCoV-2 induces protective immunity. Nature 586, 572–577.

  • Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., Jia, S.-Y., Jiang, H.-D., Wang, L., Jiang, T., Hu, Y., Gou, J.-B., Xu, S.-B., Xu, J.-J., Wang, X.-W., Wang, W., Chen, W., 2020a. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a doseescalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845–1854.

  • Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G.F., Tan, W., China Novel Coronavirus Investigating and Research Team, 2020b. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733.